Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
8.28
-0.25 (-2.93%)
At close: May 9, 2025, 4:00 PM
8.88
+0.60 (7.25%)
After-hours: May 9, 2025, 7:33 PM EDT
Arcus Biosciences Stock Forecast
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for Arcus Biosciences stock ranges from a low of $13 to a high of $44. The average price target of $25.33 forecasts a 205.92% increase in the stock price over the next year.
Price Target: $25.33 (+205.92%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Arcus Biosciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 3 | 3 |
Buy | 6 | 6 | 6 | 6 | 6 | 6 |
Hold | 2 | 2 | 1 | 1 | 1 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 12 | 12 | 11 | 11 | 10 | 11 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Morgan Stanley | Morgan Stanley | Buy Maintains $24 → $22 | Buy | Maintains | $24 → $22 | +165.70% | May 9, 2025 |
Goldman Sachs | Goldman Sachs | Hold Maintains $15 → $13 | Hold | Maintains | $15 → $13 | +57.00% | May 8, 2025 |
Wells Fargo | Wells Fargo | Buy Maintains $29 → $26 | Buy | Maintains | $29 → $26 | +214.01% | May 7, 2025 |
Barclays | Barclays | Buy Maintains $29 → $14 | Buy | Maintains | $29 → $14 | +69.08% | Apr 23, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $24 | Hold → Strong Buy | Upgrades | $24 | +189.86% | Feb 26, 2025 |
Financial Forecast
Revenue This Year
151.57M
from 258.00M
Decreased by -41.25%
Revenue Next Year
190.63M
from 151.57M
Increased by 25.77%
EPS This Year
-4.27
from -3.14
EPS Next Year
-4.36
from -4.27
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 276.2M | 297.9M | 390.3M | ||
Avg | 151.6M | 190.6M | 260.1M | ||
Low | 78.4M | 88.2M | 99.2M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 7.0% | 96.5% | 104.7% | ||
Avg | -41.3% | 25.8% | 36.5% | ||
Low | -69.6% | -41.8% | -48.0% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -3.52 | -2.79 | -1.20 | ||
Avg | -4.27 | -4.36 | -3.95 | ||
Low | -5.72 | -6.45 | -5.80 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.